When an Insurer Becomes the Health Care System

What does it mean when the company paying for your care also manages your pharmacy benefits, operates specialty pharmacies, employs physicians, runs clinics, analyzes your medical data, and determines which treatments are financially viable?

At that point, the central question is no longer whether an insurer is large. It is whether the word insurer still describes what the company fundamentally does.

UnitedHealth Group’s 2024 financial results offer a useful lens for examining this transformation. The numbers show a company operating at extraordinary scale, with insurance and health services functioning as parts of a single economic machine. At the same time, the broader structure of the health care industry reveals a pattern that is easy to miss when companies are viewed one at a time: insurers, pharmacy benefit managers, specialty pharmacies, physician groups, and care delivery organizations are increasingly connected through ownership, contracting, and data.

This is not merely consolidation. It is the construction of a new kind of institution: a vertically integrated health care platform.

The promise is coordination. The danger is that coordination can become control.

The Financial Statement Is Also a Map of Power

A corporate earnings report is usually read as a record of performance. Revenue grew. Profit changed. A business line expanded or contracted. But in a health care conglomerate, the financial statement can also reveal something more consequential: which parts of the health care journey are being brought under common control.

UnitedHealth Group illustrates this through the relationship between UnitedHealthcare and Optum. UnitedHealthcare operates the insurance business. Optum spans pharmacy services, health care delivery, technology, analytics, and related services. These are distinct businesses on paper, but they can interact at nearly every stage of a patient’s experience.

A patient may receive coverage from one entity, have a prescription processed by another, obtain a specialty drug through a related pharmacy, encounter a physician employed by an affiliated care organization, and have the resulting data analyzed by another part of the same corporate family.

Each transaction may appear ordinary. Together, they create a powerful economic architecture.

The key insight is this: scale in health care is not just about serving more people. It is about occupying more positions in the chain through which money, decisions, and information move.

Consider a simple treatment episode. A patient receives a diagnosis, sees a specialist, is prescribed a drug, fills that prescription, receives follow up care, and generates a claim. In a fragmented system, each step may be handled by a separate organization with separate incentives. In an integrated system, several of those steps may occur inside one corporate network.

That arrangement can reduce friction. Shared records may improve coordination. Purchasing power may lower costs. A system with visibility across the entire episode may be better positioned to identify duplicate tests, prevent avoidable hospitalizations, or guide patients toward effective treatment.

But integration also changes the meaning of a decision. A recommendation about where to receive care may affect not only the patient’s clinical outcome, but also the revenue of an affiliated provider. A formulary decision may influence not only drug spending, but the economics of a related pharmacy. A reimbursement rule may direct money toward a business unit that belongs to the same parent company.

The same structure that enables coordination can therefore create conflicts that are invisible at the point of service.

The question is not simply who provides care. It is who benefits when one path is chosen over another.

From Insurance Company to Health Care Operating System

The traditional insurer collects premiums, pays claims, and manages risk. Its basic skill is financial: predicting medical expenses and pricing coverage accordingly.

A vertically integrated platform does something broader. It attempts to manage the entire operating system of health care, including financing, supply, distribution, clinical delivery, and data. The insurer remains important, but it becomes one layer of a much larger structure.

This transformation can be understood through four forms of control.

1. Financial control

The insurer controls the flow of premium dollars and determines how those dollars are allocated across providers, treatments, and services. Its network design, reimbursement rules, prior authorization procedures, and benefit structures influence which forms of care are economically accessible.

2. Distribution control

Pharmacy benefit managers and specialty pharmacies influence how medicines reach patients. They negotiate prices, design formularies, manage rebates, establish preferred networks, and determine which dispensing channels are available for certain drugs.

For ordinary medications, these choices may be barely noticeable. For complex and expensive therapies, distribution is a major source of leverage. The organization that controls access to a treatment can shape the market even if it does not manufacture the treatment.

3. Clinical control

Ownership or affiliation with physician groups, clinics, home care organizations, and other providers gives an integrated company a direct role in care delivery. It can influence clinical workflows, referral patterns, staffing models, and the use of technology.

Clinical control is not necessarily harmful. A coordinated network may be more efficient than a loose collection of disconnected providers. But the larger the network, the more important it becomes to distinguish clinical integration, which improves patient care, from economic integration, which primarily redirects revenue.

4. Informational control

Every claim, prescription, referral, authorization, and appointment produces data. When one organization can connect these events across insurance, pharmacy, and clinical settings, it gains a detailed view of patient behavior and system performance.

Data can be used to improve care. It can also be used to refine pricing, steer utilization, negotiate with independent providers, and identify profitable populations or services. Information is not a passive byproduct of integration. It is one of its most valuable assets.

These four forms of control reinforce one another. Financial control directs the money. Distribution control directs the products. Clinical control directs the encounters. Informational control makes the entire structure legible to its owner.

That is why vertical integration can produce advantages that are greater than the sum of its parts. The value comes not only from owning several businesses, but from allowing each business to strengthen the others.

The Coordination Paradox

Vertical integration solves one problem by creating another.

The problem it solves is fragmentation. Health care patients routinely encounter a system in which insurers, doctors, hospitals, laboratories, pharmacies, and social service organizations operate with incomplete information and conflicting incentives. A patient can be discharged from a hospital without the primary care physician receiving timely information. A specialist can order a test without knowing that another specialist recently ordered the same one. A pharmacy can struggle to obtain authorization while the prescriber and insurer communicate through separate systems.

Integration appears to offer an answer: put more of the system under one roof, connect the data, and align the incentives.

Yet the solution may generate a new form of fragmentation at the market level. Instead of many disconnected organizations, society may end up with a few enormous ecosystems that are internally coordinated but externally difficult to challenge.

This is the coordination paradox:

The more efficiently a health care company coordinates its own network, the more leverage it may gain over everyone outside that network.

An independent physician may not be competing only with another physician. The physician may be competing with an integrated network that controls insurance design, referral flows, pharmacy relationships, and patient data. An independent pharmacy may not be competing only on price and service. It may be competing against a related pharmacy positioned through benefit design and specialty distribution rules.

The effects are difficult to observe because they rarely appear as a single dramatic decision. They accumulate through small choices:

• Which providers are included in a preferred network?
• Which pharmacies receive the most favorable terms?
• Which specialists are easiest to reach through a referral pathway?
• Which drugs require extra authorization?
• Which services are classified as medically necessary?
• Which patients are directed toward affiliated clinics?

Each decision can be defended individually as a matter of cost management or quality improvement. The strategic question is what happens when all of them point in the same direction.

This is why revenue growth alone is an incomplete measure of success. A company can grow because it is creating better care, because it is capturing more transactions, or because it has gained the ability to redirect transactions that once occurred elsewhere.

Those are very different forms of growth.

A Better Way to Read Integration: Follow the Decision, Not the Company

Traditional industry analysis often asks, “Who owns whom?” Ownership matters, but it is not enough. A company can exercise meaningful influence through contracts, reimbursement rules, preferred placement, data access, or referral arrangements without directly owning every asset involved.

A more useful framework is to follow four questions through any health care transaction.

Who controls access?

Can the patient reach the provider, drug, or service without passing through a particular gatekeeper? If access depends on a network, authorization process, or distribution channel, identify who sets the rules.

Who controls the price?

The visible price is not always the decisive one. A negotiated reimbursement rate, rebate arrangement, administrative fee, or out of pocket requirement may determine the true economics of a transaction.

Who controls the alternative?

Competition matters only when alternatives are genuinely available. If a patient can technically choose another provider but faces much higher costs or administrative obstacles, the alternative may exist in theory but not in practice.

Who receives the data?

Data about a transaction can be as valuable as the transaction itself. Ask whether information flows to an independent party, a shared platform, or a company that participates in several stages of the patient’s care.

This framework shifts attention away from corporate labels and toward practical power. It can be applied to a prescription, a hospital admission, an employer health plan, or a specialist referral.

For example, imagine two specialty pharmacies. Pharmacy A is independent. Pharmacy B belongs to a larger health care platform that also manages benefits and provides insurance. If the platform makes Pharmacy B the easiest option through network design, authorization procedures, and patient communications, the relevant question is not simply whether Pharmacy B offers a competitive price.

The deeper question is whether the platform has arranged the system so that competing pharmacies can no longer compete on equal terms.

That distinction separates efficiency from captured demand. Efficiency lowers the resources required to deliver care. Captured demand uses control over one part of the system to channel business toward another part.

The two can coexist, which is what makes the issue so difficult. An integrated company may genuinely lower administrative costs while also gaining excessive bargaining power. It may improve coordination for some patients while narrowing choice for others. It may produce operational innovations whose benefits are real, even as its position makes the market less contestable.

A serious evaluation must hold both possibilities at once.

What Financial Scale Can and Cannot Tell Us

Large financial results are evidence of capability, but not automatically evidence of social value. High revenue may indicate that a company is meeting important needs at scale. It may also indicate that the company sits at multiple tollbooths in the health care economy.

The metaphor of a tollbooth is useful because vertically integrated businesses can earn value whenever money passes between parts of the system. The company may collect premiums, administer benefits, dispense drugs, provide care, process claims, and sell analytics. It does not need to make money from every activity independently if the overall network benefits from controlling the route.

This creates a measurement challenge. Looking only at the profitability of one unit can miss the strategic value it provides to the rest of the platform. A business line that appears modestly profitable may still be valuable because it supplies data, protects a referral stream, strengthens negotiation power, or makes an affiliated service more attractive.

The right unit of analysis is therefore not always the subsidiary. It is the patient journey.

For each journey, ask:

1. How many stages are controlled by the same corporate family?
2. At which stages can the patient realistically choose an alternative?
3. Where do financial incentives and clinical recommendations intersect?
4. Does integration reduce total cost, or mainly redistribute revenue among affiliated entities?
5. Are the benefits visible to patients, or primarily visible in corporate margins?

These questions matter to investors, employers, policymakers, clinicians, and patients. They also provide a way to distinguish a healthy platform from an opaque one.

A healthy platform makes its coordination benefits measurable. It can show lower total spending, better outcomes, fewer avoidable complications, shorter delays, and clearer patient experiences. An opaque platform points to scale while making it difficult to determine how money moves or why a particular option was preferred.

Transparency is not a cosmetic virtue here. It is a competitive safeguard.

Key Takeaways

• Read health care earnings as structural documents. Do not look only at revenue and profit. Map which parts of financing, distribution, care delivery, and data are controlled by the same organization.

• Follow decisions through the patient journey. Ask who controls access, price, alternatives, and information at each step from diagnosis to treatment and follow up.

• Separate coordination from captured demand. Integration creates real benefits when it reduces waste and improves outcomes. It becomes concerning when network design mainly channels patients toward affiliated businesses without clear evidence of better care.

• Measure the whole episode, not one transaction. A low price for a drug may be offset by higher administrative costs, restricted choice, or downstream expenses. Evaluate total cost and total outcome.

• Demand usable transparency. Patients, employers, and regulators need understandable information about ownership relationships, referral incentives, pharmacy steering, reimbursement, and clinical results.

The New Question for Health Care

The future of health care may not be defined by whether insurers, providers, pharmacies, and technology companies merge. That process is already well underway. The more important question is what kind of integration society is willing to accept.

Integration can be a tool for solving fragmentation. It can connect data, reduce duplication, coordinate treatment, and make a complicated system easier to navigate. But integration can also become a method for consolidating bargaining power, restricting alternatives, and making commercial incentives harder to see.

The difference will not be determined by corporate size alone. It will be determined by whether the system can demonstrate that its internal coordination produces public value rather than merely private control.

A company that occupies many positions in health care is not automatically a problem. But it should be judged by a higher standard, because its decisions affect more than one transaction at a time. They shape the pathways through which millions of people receive care.

The defining health care question of the next decade may not be who pays for care. It may be who designs the path by which care becomes possible.

Once that question is visible, financial scale takes on a different meaning. It is no longer just a measure of how much business a company has won. It is a clue to how much of the health care system it has learned to direct.